LexaGene Life Sciences is an early-stage company developing a novel automated PCR-based bioburden testing system. The technology will be a significant improvement in the key needs of speed, ease-of-use, and sensitivity for >95% of microbial contaminants. Our initial target market is the biopharmaceutical manufacturing industry.
Looking for a particular LexaGene employee's phone or email?
The LexaGene annual revenue was $4 million in 2026.
Steve Armstrong is the COO of LexaGene.
1 people are employed at LexaGene.
LexaGene is based in Beverly, Massachusetts.
The NAICS codes for LexaGene are [541715, 54, 54171, 541, 541714, 5417].
The SIC codes for LexaGene are [873, 87].